Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus

OBJECTIVE: To evaluate the dose–response, efficacy and safety of dapirolizumab pegol (DZP) in patients with SLE. METHODS: Adults with moderately to severely active SLE (SLEDAI-2K score ≥6 and ≥1 BILAG A or ≥2 BILAG B domain scores), receiving stable CS (≤40 mg/day prednisone-equivalent), antimalaria...

Descripción completa

Detalles Bibliográficos
Autores principales: Furie, Richard A, Bruce, Ian N, Dörner, Thomas, Leon, Manuel Gustavo, Leszczyński, Piotr, Urowitz, Murray, Haier, Birgit, Jimenez, Teri, Brittain, Claire, Liu, Jiajun, Barbey, Catherine, Stach, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194804/
https://www.ncbi.nlm.nih.gov/pubmed/33956056
http://dx.doi.org/10.1093/rheumatology/keab381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194804/
https://www.ncbi.nlm.nih.gov/pubmed/33956056
http://dx.doi.org/10.1093/rheumatology/keab381

Ejemplares similares